The U.S. Food and Drug Administration (FDA) has maintained a considerable track record in the litigation landscape over the past few years. With several key advantages, the agency has emerged victorious on numerous accounts. However, in certain highly visible situations, the achievement tally is less assuring, as brought to light by Jonathan Berman and Colleen Heisey at the global law firm, Jones Day.
In litigation against the FDA, the odds might appear to be stacked in its favor, immediately adding a daunting dimension to the task. The agency’s robust litigation performances have been well documented, demonstrating the FDA’s ability to both draw on its interpretative discretion and manifest regulatory dexterity amidst rapidly evolving legal challenges.
Nevertheless, imperfections are clearly visible within this record of successes. Just as the FDA has demonstrated its strength in some quarters, it has also unveiled its vulnerabilities in others. Especially in the public eye, where intense scrutiny is involved, the agency would appear to be less successful. The nature of the cases, potential precedents set, and repercussions faced by the FDA are factors that can impact the agency’s overall standing.
The entire overview of the FDA’s litigation history, merits, and shortcomings is further delved into by attorneys Jonathan Berman and Colleen Heisey in their analysis, which can be similarly helpful to legal professionals keenly tracking the developments in this corner of the legal world. The complete understanding of these dimensions is crucial for future engagements with the agency as it continues to assert its regulatory authority.
Explore the entirety of Berman and Heisey’s analysis
here to unravel the subtleties of FDA’s recent litigation records.